It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aim
The diagnosis of hypertrophic cardiomyopathy (HCM) with moderate hypertrophy is challenging. Hypertensive heart disease (HHD) is the most common differential diagnosis that mimics the LVH of HCM. The aim of this study was to compare the QRS duration in HCM and HHD to create a novel diagnostic tool to identify primary HCM.
Methods and results
We conducted an international retrospective multicentre study enrolling patients with true HCM and HHD. A total of 547 individuals with HCM and 139 with HHD were included. The median QRS duration was significantly shorter in HCM than in HHD (88 ms [80–94] vs. 98 ms [88–108]; P < 0.01). Multivariable logistic regression identified for the novel diagnostic HCM (D‐HCM) score: absence of antihypertensive drugs (+2); family history of unexplained sudden death (+2); QRS duration [<95 ms] = +1; maximum wall thickness (mm) [≥17] = +1. A cumulative QRS‐HCM score ≥2 supports the diagnostic certainty of true HCM with a sensitivity of 79%, specificity of 99%, negative predictive value (NPV) of 55%, and positive predictive value (PPV) of 99%.
Conclusion
The QRS duration in patient with HCM is significantly shorter compared with patients with HHD‐related LVH. QRS duration can be used as a diagnosis marker to distinguish between HCM and HHD. The D‐HCM score is a novel, simple, and accurate diagnosis tool for HCM patients with mild to moderate phenotypes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Biscond, M. 2 ; Dognin, N. 3 ; Strube, C. 3 ; Mondoly, P. 4 ; Réant, P. 5 ; Sarrazin, J.F. 3 ; Galinier, M. 4 ; Champagne, J. 3 ; Rollin, A. 4 ; Carrié, D. 4 ; Cochet, H. 5 ; Lairez, O. 4 ; Philippon, F. 3 ; Ferrières, J. 4 ; Maury, P. 4 ; Steinberg, C. 3 1 Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada, Hôpital Rangueil, University of Toulouse, Toulouse, France
2 Collège des Sciences Humaines, Université de Bordeaux, Bordeaux, France
3 Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada
4 Hôpital Rangueil, University of Toulouse, Toulouse, France
5 Hôpital Haut‐Lévêque, Bordeaux University, Bordeaux, France





